Efficacy end points (full analysis set)
| End point | Placebo (n=442) | Acotiamide (n=450) | p Value |
| Primary end point | |||
| Overall treatment efficacy | 34.8 | 52.2 | <0.001 |
| Elimination rate for all three symptoms | 9.0 | 15.3 | 0.004 |
| Secondary end point | |||
| Elimination rate of individual symptoms at last survey point | |||
| Postprandial fullness | 16.6 | 22.7 | 0.026 |
| Upper abdominal bloating | 28.5 | 34.5 | 0.084 |
| Early satiation | 25.4 | 37.8 | <0.001 |
Patients achieving the two primary overall efficacy end points: “extremely improved” or “improved” were considered responders.
Elimination rate: the proportion of patients who achieved elimination of all of the three symptoms: postprandial fullness, upper abdominal bloating and early satiation (no symptoms) at the last survey point.